Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07469228 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,043
- Enrollment target
NCT07469228: Completed Phase 1 study, sponsored by Sun Pharmaceutical Industries.
NCT07469228 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 1,043 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1638% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07469228, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,043 participants
- Enrollment target
Study Summary
To demonstrate the efficacy, therapeutic equivalence and safety of tretinoin gel microsphere, 0.04% (Sun Pharmaceutical Industries, Inc.) and RETIN-A MICRO ® (tretinoin) gel microsphere, 0.04% (Reference Listed Drug) in the treatment of acne vulgaris.
Primary Outcome
Mean Percentage change in the inflammatory (papules and pustules) \& non-inflammatory (comedones) lesion counts
Interventions
- DRUG Placebo Control
- DRUG Tretinoin Gel Microsphere, 0.04%
- DRUG RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,043 participants |
| Start Date | 2025-08-04 |
| Est. Completion | 2025-12-15 |
| Phase | Phase 1 |
What the finished NCT07469228 record still lists
NCT07469228 is an interventional study that assigns participants to a tested intervention. Its 1,043 participants enrollment target places it among the larger protocols in the corpus, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1638% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo Control is the first listed.
NCT07469228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07469228 about?
NCT07469228 is a clinical study titled "A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris". To demonstrate the efficacy, therapeutic equivalence and safety of tretinoin gel microsphere, 0.04% (Sun Pharmaceutical Industries, Inc.) and RETIN-A MICRO ® (tretinoin) gel microsphere, 0.04% (Reference Listed Drug) in the treatment of acne vulgaris.
What is the current status of trial NCT07469228?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,043 participants. The study started on 2025-08-04. Estimated completion is 2025-12-15.
What interventions are being tested in trial NCT07469228?
The interventions under investigation include: Placebo Control (DRUG), Tretinoin Gel Microsphere, 0.04% (DRUG), RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04% (DRUG).
Who is sponsoring clinical trial NCT07469228?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07469228's enrollment target sits among peer trials
1,043 6th of 2000 higher than 1,995 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04685616 · 1,042 participants · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- NCT06564948 · 1,040 participants · NA
Treatment for Individuals Interacting with the Criminal Justice System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI